Clinical trialNCT00789256CompletedInterventional

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

SponsorDartmouth-Hitchcock Medical CenterEnrollment26Acute Myelogenous LeukemiaMyelodysplastic Syndromes

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jeffrey Bubis, DO
Integrated Community Oncology Network
Principal Investigator
clinicaltrials.gov ↗
Marc Gautier, MD
Dartmouth-Hitchcock Medical Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Integrated Community Oncology Network
Jacksonville, Florida, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bortezomib →Melphalan →Melphalan and bortezomib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2004
Primary completion: 31 Dec 2008
Completion: 31 Dec 2008
Last update posted: 24 Oct 2018
Registered enrollment: 26
Registry id: NCT00789256

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.